Equities researchers at HC Wainwright started coverage on shares of GALAPAGOS NV/S (NASDAQ:GLPG) in a research note issued to investors on Thursday, March 28th, Marketbeat reports. The brokerage set a “buy” rating and a $136.00 price target on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 17.82% from the stock’s previous close.
GLPG has been the subject of several other research reports. Zacks Investment Research downgraded GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a research note on Friday, March 1st. BidaskClub downgraded GALAPAGOS NV/S from a “hold” rating to a “sell” rating in a research note on Wednesday, March 27th. Cantor Fitzgerald set a $130.00 target price on GALAPAGOS NV/S and gave the stock a “buy” rating in a research note on Tuesday, March 26th. Cowen reissued a “buy” rating on shares of GALAPAGOS NV/S in a research note on Friday, February 22nd. Finally, Leerink Swann started coverage on GALAPAGOS NV/S in a research note on Friday, February 22nd. They set an “outperform” rating and a $140.00 target price for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $125.83.
Shares of GLPG traded up $1.45 during midday trading on Thursday, reaching $115.43. 165,448 shares of the stock were exchanged, compared to its average volume of 201,716. The company has a market capitalization of $5.91 billion, a P/E ratio of -43.72 and a beta of 1.68. GALAPAGOS NV/S has a twelve month low of $85.00 and a twelve month high of $125.48.
GALAPAGOS NV/S Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
See Also: How a Back-End Load Mutual Fund Works
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.